[Antithymocyte globulin used for treatment of severe acute graft versus host disease after haploidentical bone marrow transplantation].
The objective of study was to investigate the effect of low-dose antithymocyte globulin (ATG) on steroid-resistant severe acute graft versus host disease (aGVHD). Six patients with steroid-resistant severe aGVHD after haploidentical bone marrow transplantation (BMT) received the treatment with ATG at a low dose of 1.25 mg/kg for 3 - 5 doses every other day. The results showed that 3 out of 6 patients got completely remission (CR), among them 2 patients have still been in disease-free survival, 1 patient died from leukemia relapse. 1 out of the other 3 patients got partial remissin (PR), 2 patients were aggravated. The other 3 patients all died from GVHD. The major complications observed in these patients were infections. In conclusion, low-dose ATG is effective for some patients with steroid-resistant severe aGVHD, and has not severe side effect. To strengthen environmental protection should be considered as important for prevention of infection.
Liu
Jing
J
Department of Hematology, Air Force General Hospital of PLA, Beijing 100036, China. liujingemail@126.com
Wang
Heng-Xiang
HX
Duan
Lian-Ning
LN
Xue
Mei
M
Zhu
Ling
L
Yang
Hong-Min
HM
Ding
Li
L
Ji
Shu-Quan
SQ
D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000209:etiology; D006680:HLA Antigens / Q000276:immunology; D006239:Haplotypes / Q000276:immunology; D006801:Humans; D008297:Male; D055815:Young Adult
D000961:Antilymphocyte Serum; D006680:HLA Antigens